454 related articles for article (PubMed ID: 26266887)
1. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
[TBL] [Abstract][Full Text] [Related]
2. A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up.
Pacilio M; Ventroni G; Cassano B; Ialongo P; Lorenzon L; Di Castro E; Recine F; Sternberg CN; Mango L
Ann Nucl Med; 2016 Feb; 30(2):163-8. PubMed ID: 26613714
[TBL] [Abstract][Full Text] [Related]
3. Detection and quantification of
Mínguez P; Gómez de Iturriaga A; Fernández IL; Rodeño E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):20-27. PubMed ID: 28645684
[TBL] [Abstract][Full Text] [Related]
4. The Italian multicentre dosimetric study for lesion dosimetry in
Pacilio M; Cassano B; Chiesa C; Giancola S; Ferrari M; Pettinato C; Amato E; Fioroni F; Lorenzon L; Pellegrini R; Di Castro E; Pani R; Cremonesi M
Phys Med; 2016 Dec; 32(12):1731-1737. PubMed ID: 27662815
[TBL] [Abstract][Full Text] [Related]
5. The potential of
Murray I; Chittenden SJ; Denis-Bacelar AM; Hindorf C; Parker CC; Chua S; Flux GD
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1832-1844. PubMed ID: 28612079
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases.
Chittenden SJ; Hindorf C; Parker CC; Lewington VJ; Pratt BE; Johnson B; Flux GD
J Nucl Med; 2015 Sep; 56(9):1304-9. PubMed ID: 26182965
[TBL] [Abstract][Full Text] [Related]
7. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases.
Hindorf C; Chittenden S; Aksnes AK; Parker C; Flux GD
Nucl Med Commun; 2012 Jul; 33(7):726-32. PubMed ID: 22513884
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases.
Yoshida K; Kaneta T; Takano S; Sugiura M; Kawano T; Hino A; Yamamoto T; Shizukuishi K; Kaneko M; Zurth C; Inoue T
Ann Nucl Med; 2016 Aug; 30(7):453-60. PubMed ID: 27272279
[TBL] [Abstract][Full Text] [Related]
9. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
Humm JL; Sartor O; Parker C; Bruland OS; Macklis R
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):898-906. PubMed ID: 25832684
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study on the potential of
Mínguez P; Rodeño E; Fernández I; Esteban A; Martínez-Indart L; Gómez de Iturriaga A
Med Phys; 2021 Mar; 48(3):1395-1403. PubMed ID: 33372286
[TBL] [Abstract][Full Text] [Related]
11. Compartmental Model for
Taprogge J; Murray I; Gear J; Chittenden SJ; Parker CC; Flux GD
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):884-892. PubMed ID: 31349058
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
[TBL] [Abstract][Full Text] [Related]
14. Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer.
Pratt BE; Hindorf C; Chittenden SJ; Parker CC; Flux GD
Nucl Med Commun; 2018 Feb; 39(2):125-130. PubMed ID: 29189490
[TBL] [Abstract][Full Text] [Related]
15. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Value of Quantitative Bone SPECT/CT Before
Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Single Photon Emission Computed Tomography of Alpha Particle-Emitting Radium-223.
Abou DS; Rittenbach A; Tomlinson RE; Finley PA; Tsui B; Simons BW; Jha AK; Ulmert D; Riddle RC; Thorek DLJ
Cancer Biother Radiopharm; 2020 Sep; 35(7):520-529. PubMed ID: 32182119
[No Abstract] [Full Text] [Related]
18. The Relationship Between Total Lesion Activity on
Filippi L; Basile P; Schillaci O; Bagni O
Cancer Biother Radiopharm; 2020 Aug; 35(6):398-403. PubMed ID: 32109140
[TBL] [Abstract][Full Text] [Related]
19. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
20. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.
Pandit-Taskar N; Larson SM; Carrasquillo JA
J Nucl Med; 2014 Feb; 55(2):268-74. PubMed ID: 24343987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
